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Background: In cancer immunotherapy, dendritic cells (DCs) play a fundamental role in the dialog between innate
and adaptive immune response, but several immunosuppressive mechanisms remain to be overcome. For example,
a high number of CD4+CD25++Foxp3+ regulatory T-cells (Foxp3+Tregs) have been observed in the peripheral blood
and tumor microenvironment of cancer patients. On the basis of this, we conducted a study on DC-based
vaccination in advanced melanoma, adding low-dose temozolomide to obtain lymphodepletion.
Methods: Twenty-one patients were entered onto our vaccination protocol using autologous DCs pulsed with
autologous tumor lysate and keyhole limpet hemocyanin. Patients received low-dose temozolomide before
vaccination and 5 days of low-dose interleukin-2 (IL-2) after vaccination. Circulating Foxp3+Tregs were evaluated
before and after temozolomide, and after IL-2.
Results: Among the 17 evaluable patients we observed 1 partial response (PR), 6 stable disease (SD) and 10
progressive disease (PD). The disease control rate (PR+SD = DCR) was 41% and median overall survival was 10
months. Temozolomide reduced circulating Foxp3+Treg cells in all patients. A statistically significant reduction of
60% was observed in Foxp3+Tregs after the first cycle, whereas the absolute lymphocyte count decreased by only
14%. Conversely, IL-2 increased Foxp3+Treg cell count by 75.4%. Of note the effect of this cytokine, albeit not
statistically significant, on the DCR subgroup led to a further 33.8% reduction in Foxp3+Treg cells.
Conclusions: Our results suggest that the combined immunological therapy, at least as far as the DCR subgroup is
concerned, effectively reduced the number of Foxp3+Treg cells, which exerted a blunting effect on the growth-
stimulating effect of IL-2. However, this regimen, with its current modality, would not seem to be capable of
improving clinical outcome.
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Dendritic cells (DCs) present antigens to naïve T-
lymphocytes and regulate the activation of the adap-
tive response, playing a fundamental role in the dialog
between innate and adaptive immune response [1].
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reproduction in any medium, provided the orThe tumor microenvironment is immunosuppressive
because of the presence of weak self or self-like antigens,
the absence of a real danger signal and the presence of
tumor immunosuppressive signals. However, recent expe-
riences of DC vaccination in melanoma show that proven
immunostimulation usually correlates with positive cli-
nical outcome [2].
A review of 54 DC vaccination trials showed that the
use of mature DCs (mDCs) rather than immature DCs
(iDCs), the adjuvants of choice and confirmed immu-
nization strongly influence clinical outcome [3]. Thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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must aim to enhance antigen-specific cytotoxic T-cells
and to decrease immunosuppression, perhaps through
CD4+CD25++Foxp3+ regulatory T cell (Foxp3+Treg)
lymphodepletion or through the use of new molecules,
for example, anti-CTLA-4 or anti-PD1, or immuno-
stimulators, e.g. CpG [4-7]. Foxp3+Tregs, a subset of
CD4+ T cells, were first described by Sakaguchi [8], who
discovered that these cells constitutively express high
levels of interleukin-2 (IL-2) receptor α chain (CD25),
preventing autoimmune diseases in mice. These cells have
since been shown to be involved in the development of
autoimmunity, allergy, and rejection in transplant medi-
cine and in the suppression of immune responses to
cancer.
Higher numbers of Foxp3+Tregs have been observed
in the peripheral blood of cancer patients, in ascites, in
the tumor microenvironment, and in tumor draining
lymph nodes in a variety of solid cancers [9]. There
appears to be a two-way relationship between DCs and
Foxp3+Tregs. iDCs are capable of inducing the peri-
pheral formation of Foxp3+Tregs [10]. Furthermore,
mDCs are able to convert resting autologous T-cells into
Foxp3+Tregs via an indoleamine 2,3-dioxygenase mech-
anism. This method of Foxp3+Treg expansion is still
dependent on CD80/CD86 ligation and endogenous IL-2
production [11]. Foxp3+Treg depletion can evoke effective
tumor immunity and has led to tumor rejection in several
animal models [8,12]. Although it is not clear whether
chemotherapy can be used to counter Foxp3+Treg-
derived tumor protection, it would, however, seem to acti-
vate the immunocompetence needed for vaccine response
[13]. Low-dose metronomic cyclophosphamide regimens
have been shown to deplete the Foxp3+Treg cell popula-
tion in humans [14]. However, it remains uncertain
whether other chemotherapeutic agents can induce such
Foxp3+Treg depletion. Temozolomide (TMZ), for ex-
ample, is capable of modulating blood Foxp3+Tregs. In
phase III trials TMZ and dacarbazine have shown similar
response rates [15,16]. TMZ has also been used in asso-
ciation with low-dose IL-2 in patients with advanced
melanoma, producing durable clinical responses [17], and
in combination with a telomerase peptide vaccination,
showing encouraging results [18]. In 2009 Banissi and
coworkers reported that low-dose metronomic TMZ regi-
mens (0.5 and 2 mg/kg for 21 days) induced a significant
decrease in Foxp3+Treg/CD4+ ratios in the spleen of
tumor-bearing animals [19]. Similarly, Su and coworkers
observed a specific decrease in CD4+ T-cells in patients
treated with TMZ [20].
On the basis of these observations we decided to make
an amendment of our study [21] protocol on dendritic
cell-based vaccination in advanced melanoma by adding
low-dose TMZ in an attempt to deplete the Foxp3+Tregpopulation. The present study presents the results ob-
tained from this amendment.
Methods
Patients
From January 2007 to January 2009, 21 patients with ad-
vanced melanoma were entered onto a vaccination proto-
col using autologous DCs pulsed with autologous tumor
lysate (ATL) or autologous tumor homogenate (ATH) and
keyhole limpet hemocyanin (KLH). Low-dose TMZ was
administered before vaccination, as per the study amend-
ment. Inclusion criteria were age < 70 years, histologically
confirmed diagnosis of melanoma, measurable disease
(excluding brain metastases), previous removal of one or
more metastatic lesions from which a sufficient quantity
of ATL/ATH had been obtained for at least 6 vaccinations,
performance status (PS) ≤ 2 (according to ECOG criteria),
life expectancy > 4 months.
Treatment
The first 16 patients were treated (only for the first 6 cy-
cles) in the 14 days before vaccination with low-dose
TMZ: 75 mg/m2/day (max 100 mg/day) (days −14 to −1).
In an attempt to further improve compliance to treatment,
the last 5 patients received the same dosage/day of TMZ
for only 7 days before each vaccination (day −7 to −1).
Patients were then vaccinated with mDCs pulsed with
ATL or ATH via intradermal injection using an insulin
needle. Several injections were made (average 6–8) near
the groin or the armpit in non metastatic, non lympha-
denectomized sites every two weeks for the first 4 vaccina-
tions and then monthly thereafter until progression
occurred or for a maximum of one year. Subcutaneous IL-
2 (Novartis, Italy) 3,000,000 IU/day was administered
48 hrs after each vaccination for 5 consecutive days (from
days +2 to +6) (Figure 1). Delayed-type hypersensitivity
(DTH) assessment was carried out before the first vaccin-
ation, after the 4th vaccination, and every 2 vaccinations
thereafter. The disappearance of or an important reduc-
tion in pre-existing lesions in concomitance with disease
progression in other sites was considered as a mixed re-
sponse (MR). The best response obtained was considered
for evaluation purposes. Toxicity or adverse events were
assessed after each vaccine administration. Circulating
Foxp3+Tregs were evaluated on days −14, 0 and imme-
diately after IL-2 during the first and the fourth cycle
(Figure 1).
The study protocol and, subsequently, the amend-
ment, were reviewed and approved by the local Ethics
Committee (2001 and 2007, respectively), in accordance
with ethical standards laid down in the 1964 Declaration
of Helsinki, and authorized in July 2001 by the Italian
Ministry of Health. All patients gave informed written
consent to receive treatment.
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Surgically removed tumor samples were mechanically
dispersed to create a single-cell suspension. The largest
pieces were incubated at 37°C in enzyme mix (collage-
nase 0.1%, hyaluronidase 0.01%, DNAse 0.1%, Sigma,
Milan, Italy) in RPMI 1640, (PAA Laboratories GmbH,
Pasching, Austria) for 3 h. At the end of incubation the
pellets were washed 3 times with PBS and incubated for
at least 20 min in sterile distilled water. Lysis was moni-
tored by light microscope. Larger particles were removed
by centrifugation (10 min at 600 g) and the supernatant
was passed through a 0.2-μm filter. Protein contents
were determined and aliquots, after verifying sterility,
were stored at −80°C until use.
Autologous tumor homogenate (ATH) preparation
In some cases the surgically removed tissue was stored
at −80°C because the decision to vaccinate had still not
been taken. Frozen tissue fragments were pulverized in a
dismembrator after immersion in liquid nitrogen. Pul-
verized tissue was then suspended in PBS. After centri-
fugation, the supernatant was treated as described above.
DC generation
DC were prepared from peripheral blood monocytes
(PBMCs) obtained by leukapheresis without previous
mobilization. Five to nine liters of blood were processed
in each collection. PBMCs were purified on Ficoll-Paque.
An aliquot of PBMCs was utilized immediately for DC
generation and the rest was frozen in bags and cryo-
preserved in nitrogen vapors for use at a later date (4–5
bags/collection). Fresh PBMCs or thawed PBMCs were
incubated in tissue culture flasks with CellGro DC
medium (Cell Genix, Freiburg, Germany) at 10 × 106 cells/
ml for 2 h. Non-adherent cells were discarded and ad-
herent cells were incubated in CellGro DC medium
containing 1000 IU/ml rhIL-4 (Cell Genix, Freiburg,Day -14 -13-12 -11 -10 -9 -8 -7-6 -5 -4 -3 -2 -1   
TMZ 75mg/m2/die
Vaccine Foxp3+Treg blood samples (1st and
Figure 1 Flow-chart: treatment and Foxp3+Treg blood sample scheduGermany) and 1000 IU/ml rhGM-CSF (Cell Genix) for
7 days to generate a DC-enriched cell population. On
day 6, 90% of the DC culture was pulsed with ATL/ATH
(100 mg/ml), while the remaining 10% was pulsed with
KLH (50 mg/ml). Both cultures were then incubated over-
night. On day 7, the cells were defined as immature DCs
(iDCs). After eliminating the previous culture medium,
pulsed iDCs were cultured for a further 2 days with a
cocktail of cytokines (TNFα, IL-1β, IL-6, Cell Genix;
PGE2, Pfizer, Latina, Italy). On day 9 they were defined as
mature DCs (mDCs). mDCs (median 10×106, range 4.9–
17 × 106) were removed, washed, suspended in sterile
saline solution and sent immediately for therapeutic injec-
tion. The vaccine was maintained at room temperature
and administered within one hour of preparation. The
entire process, from leukapheresis to injection, was carried
out in accordance with Good Manufacturing Practice
(GMP) guidelines.
Quality control of dendritic cell vaccine
Safety test
Endotoxin (≤ 0.5 EU/ml), germ-free and mycoplasma-
free tests were performed in accordance with European
Pharmacopoeia guidelines.
Phenotypic analysis
DC vaccine phenotype was determined by flow cytometry
using a BD FACSCanto flow cytometer (Becton Dickinson,
Milan). The following monoclonal antibodies with related
isotype controls were used: anti-CD80, anti-CD86, anti-
HLA-DR (BD Pharmingen, San Diego, CA, USA), and
anti-CD83 (Beckman Coulter, Milan, Italy).
Analysis of CD4+CD25++Foxp3+ regulatory T cells
Foxp3+Treg levels (%) in whole blood CD4+ lymphocytes
were measured using a flow cytometry assay. Cells were
stained with combinations of the following antibodies:  0 +1 +2 +3 +4 +5           +6
IL-2 3MUI/dies.c
 4th  cycles); TMZ, temozolomide; IL-2 interleukin-2  
le.
Ridolfi et al. Journal of Translational Medicine 2013, 11:135 Page 4 of 10
http://www.translational-medicine.com/content/11/1/135Foxp3 Alexa Fluor 488/CD4 PE-Cy5/CD25 PE (Biolegend;
San Diego, CA, USA). Test tubes were labeled, incubated
in the dark for 30 min and then washed with phosphate
buffered saline. For intracellular staining of Foxp3, sam-
ples were fixed and permeabilized using Foxp3 Fix/Perm
and Perm Buffer (Biolegend) according to the manufac-
turer’s instructions.
Data acquisition and analysis were performed using the
FACS ARIA II flow cytometry system and FACS Diva™
software (BD Biosciences; Mountain View, CA, USA).
Lymphocytes were gated via their forward and side scatter
properties, and T-cells were identified on the basis of their
expression of CD4, CD25 high and Foxp3. The absolute
concentration of Foxp3+Treg cells was quantified by deter-
mining the percentage of fluorescence-positive cells within
the forward/side scatter lymphocyte gate, and by multiply-
ing this percentage by the absolute lymphocyte concentra-
tion determined using an automated hematology analyzer,
Sysmex XE2100, (Sysmex Europe GmbH, Hamburg-
Norderstedt, Germany). As this furnished a phenotypic
evaluation of Foxp3+Treg levels, no functional or suppres-
sion assays were performed to assess Foxp3 + Treg levels.
In vivo monitoring (DTH)
ATL or ATH (10 μg) and KLH (5 μg) were each suspended
in 500 μl of PBS and injected intradermally into the fore-
arm of the patient. PBS alone was used as negative control.
Statistical evaluations
Survival was calculated as the time between the date of the
first treatment cycle and the date of death from any cause.
Non-parametric ranking statistics (median test) were used
to analyze the relationship between the percent change
and patient status (progression or clinical benefit). The
paired T-test was used to determine the level of signifi-
cance in lymphocyte count changes from baseline to T1 or
T2. Statistical analyses were carried out with SAS Statistical
software (version 9.3, SAS Institute, Cary, NC, USA).
Results
Characteristics of DCs
DC vaccine was generated successfully from all the pa-
tients. Leukapheresis provided a sufficient number of
PBMCs (median, 3.5×109; range 1.7–9×109) to prepare
an average of 5 cycles of vaccine (range 3–8 cycles) per
patient. All vaccines were found to be compliant with
the safety testing. The analysis of mDC lineage markers,
carried out on dendritic cells obtained from both fresh
and frozen PBMCs, revealed high expression of CD83,
HLA-DR, CD80 and CD86.
Clinical results
Patients were required to undergo a minimum of 4
vaccinations to be considered evaluable, and 17 out of21 patients satisfied the criteria. Of the 4 patients who
were not assessable, one experienced severe disseminated
intravascular coagulation before the first cycle, 2 showed
a rapid worsening of clinical conditions and did not
complete the first treatment cycle and one developed
symptomatic brain metastases after the first vaccination.
Patient characteristics were as follows: 12 males, 5
females, median age 57 years (range 35–73), 4 stage M1a,
3 M1b and 10 M1c, all pretreated (Table 1). The first 12
evaluable patients received a median TMZ dose/cycle
of 1400 mg, while the remaining 5 were administered
700 mg. Only 2 patients were forced to reduce the dose of
TMZ because of intolerance (Table 2). No major toxicities
were observed. The most frequent adverse events to TMZ
were grade II nausea and vomiting. There were no cases
of hematological toxicity. Toxicities linked to vaccination
plus IL-2 were mainly flu-like syndromes (grade I-II asthe-
nia and fever) after IL-2 administration and local reactions
in the vaccine injection sites.
Up to December 2011 (last follow up) 1 partial response
(PR) of 6 months (one of the 5 patients who received
TMZ for 7 days), 6 cases of stable disease (SD) with a
median duration of 6.5 months (among whom another
patient from the group given 7-day TMZ) and 10 cases of
progressive disease (PD) had been observed. The disease
control rate (DCR) was 41% (7/17 patients). Median over-
all survival (OS) was 10 months (95% CI 6–14) with a
median follow up of 38 months (range 3–41). Six of the
7 patients who achieved disease control (DCR) had posi-
tive DTH: one patient who obtained PR showed positivity
for KLH alone, while 5 SD patients were positive to lysate
or homogenate. The remaining SD patient had negative
DTH tests. Among those who progressed, 3 showed weak
positivity to DTH (Tables 2 and 3).
Only 4 patients underwent further treatment after vac-
cination, 3 of whom with ipilimumab. A further 4 patients
were treated before vaccination with ipilimumab. It can-
not be ruled out that OS was not influenced by treatment
with this monoclonal antibody.
CD4+CD25++Foxp3+ regulatory T cells
Analysis was based on the absolute number of Foxp3+Tregs,
and 14 of the 17 evaluable patients (4 of whom had re-
ceived the 7-day TMZ treatment) had adequate blood
samples. A significant decrease of 60.5% in the absolute
number of Foxp3+Tregs was observed in these patients
after the first treatment cycle, including those who under-
went 7-day TMZ (p = 0.017) (Figure 2). Conversely, evalu-
ation during the 4th cycle highlighted a non significant
reduction of 5.5% in Foxp3+Tregs (p = 0.288) (Table 4). A
14% reduction in all lymphocytes was observed in this
group (p = 0.020).
We further divided the 14 patients into 2 groups com-
prising those who achieved DCR and those who did not
Table 1 Patient characteristics
Patient ID Gender Age (years) Site of evaluable disease M1 classification Previous treatments
28 M 66 Lymph nodes, lung, liver, pelvis a BIOCT
29 F 43 Lymph nodes, lung, liver, skin c BIOCT
30 M 69 Lymph nodes, skin, bone c BIOCT
31 M 57 Lymph nodes, skin a BIOCT
32 M 59 Lymph nodes, lung, liver c BIOCT
33 F 44 Liver, skin c BIOCT, anti-CTLA4Ab
(interrupted after 2 cylces
due to grade IV toxicity)
34 F 45 Lung, lymph nodes, soft tissue b CT and RT
35. M 73 Lymph nodes, soft tissue, peritoneum a Surgery and RT
36 M 68 Skin, lung b BIOCT
37 F 35 Pelvis, lymph nodes,skin, peritoneum, lung b CT, anti-CTLA4Ab
38 M 51 Lymph nodes, skin, lung c anti-CTLA4Ab, CT
39 M 62 Lymph nodes, skin, adrenal gland c Leg Stopflow CT, ECT
40 M 47 Lymph nodes,skin, peritoneum c anti-CTLA4Ab, CT, RT
41 F 57 Lymph nodes a IFN, antiCD137Ab, CT
42 M 49 Lymph nodes, soft tissue, colon c CT
43 M 60 Adrenal gland, soft tissue, lung c CT
44 M 57 Lung, liver, lymph nodes, soft tissue c CT, IFN
Summary Male 12 Median M1a:4
M1b:3
Female 5 57 (range 35–73) M1c:10
M Male, F Female, BIOCT Biochemotherapy, CT Chemotherapy, RT Radiotherapy, INF Interferon-alfa, ECT Electrochemotherapy, anti-CTLA4Ab, antibody against
CTLA4, antiCD137Ab, antibody against.
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duction of 30.2% (range −71.3% to +2.8%) was observed in
Foxp3+Tregs (p = 0.161). Similarly, statistical significance
was not reached for the 76.4% (range −84.9% to +72.2%)
reduction in Foxp3+Tregs observed in PD patients.
A median variation of −11.9% (range −30.0% +2.1%)
and −17.1% (range −72% +51.7%) in all lymphocytes was
registered in DCR and PD patients, respectively p values
were not significant in either group.
Taking into consideration the variations from day 0 to
after the end of IL-2 treatment, an overall increase of
75.4% was registered in the entire group (only 12 patients
were evaluable because post-IL-2 blood samples were
not available in 2 DCR patients) during the first cycle
(Figure 3). When the 2 groups were analyzed separately,
this result converted into a +388.9% increase in PD
patients, but a −33.8% reduction in DCR patients. Lym-
phocyte values were as follows: +15.6% in all 12 patients
(range −71.5% +104.5%), +32.9% (range −29.5% +104.5%)
in PD and −22.2% (range −71.5% +23.6%) in DCR pa-
tients. None of these variations was statistically signifi-
cant. Interestingly, a non statistically significant increase
of +53.2%. was observed for DCR patients during the
4th cycle.In the 9 patients for whom baseline (time zero) and
final (after IL-2 at the end of the 4th treatment cycle)
blood samples were available, we observed a −20.3%
(range −84.0% to +569.7%) reduction in Foxp3+Tregs,
which, however, did not reach statistical significance even
when the two groups (DCR and PD) were considered sep-
arately. In the same 9 patients we also observed a reduc-
tion in the total lymphocyte count of −4.0% (range −76.0%
to +32.8%), with values of +7.8% (range:–76.0% to 32.8%)
in PD patients and −16.4% (range −33.5% to +16.9%) in
DCR patients (median test p = 0.416) (Table 4).
Discussion
A recent review of results from clinical trials of dendritic
cell vaccination shows that immunological response is
related to improved clinical outcome [3]. Our previous
experience with 27 patients treated with dendritic cell
vaccination for metastatic melanoma further confirms
this finding in that we observed significantly better over-
all survival among patients with positive DTH skin test-
ing after treatment (22.9 months positive DTH vs. 4.8
months negative DTH) [22]. The same review by Nakai
also underlined the importance of adjuvants aimed at re-
ducing immune suppression (e.g. lowering Foxp3+Treg




























28 1400 12 12.6 +++ +++ - SD 9 12 None
(11.5–17)
29 1400 first 2 cycles,
700 last 2 cycles
4 7.7 – – – PD 3 None
(5.4–8.6)
30 1400 5 11,9 – – – PD 6 None
(11.5–14)
31 1400 8 12.6 – – – SD 4 7 None
(11.1–15.3)
32 1400 first 3 cycles,
700 last cycle
5 8.5 – – – PD 6 None
(7.5–10)
33 1400 8 8.8 +++ +++ + SD 4 12 BIOCT
(4.9–10)
34 1400 6 10.1 – – – PD 14 None
(6.9–14.5)
35 1400 17 9.4 ++ – – SD 10 36+ antiCTLA4Ab
(6.5–10.8)
36 1400 6 9.8 + + – SD 9 41+ antiCTLA4Ab
(8.3–13.9)
37 1400 first cycle,
700 last 3 cycles
17 7.8 ++ – – SD 4 16 None
(5.7–10)
38 1400 11 9.3 – + – PD 12 None
(8.1–10.8)
39 1400 5 10 – – – PD 7 None
(10–10)
40 1400 5 11.3 – – – PD 4 None
(10–15)
41 700 10 9.3 – +++ – PR 6 14 None
(5.8–10)
42 700 4 10 – – – PD 4 None
(10–10)
43 700 5 10 + + – PD 8 None
(9.6–13.8)
44 700 7 10 – + – PD 10 antiCTLA4Ab
(10–10)
BIOCT Biochemotherapy, anti-CTLA4Ab antibody against CTLA4, PD Progressive disease, SD Stable disease,PR Partial response, Os Overall survival, DTH Delayed-
type hypersensitivity, KLH Keyhole limpet hemocyanin, L/H Lysate/homogenate, + Patients alive in December 2011.
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lation (e.g. anti-CTLA4 or anti-PD1 antibodies). A de-
crease in Foxp3+Tregs has been reported to improve
cytotoxic T cell response and would appear to be related
to a better response to vaccines [23-25]. Bjoern and co-
workers observed a reduction, albeit not statisticallysignificant, in Foxp3+Treg cell numbers among patients
who obtained at least disease stabilization with respect
to those who progressed [26]. The authors thus hypothe-
sized that these cells may exert effective immune
suppressant action in vivo and carried out further re-
search aimed at identifying new strategies to reduce
Table 3 Clinical response in 17 evaluable patients
No. (%) Clinical benefit Median OS (months)
PR 1 (5.8) 7/17 (41%) 14
SD 6 (35.2)
PD 10 (58.8) 6.5
All 17 patients 10
PR Partial response, SD Stable disease, PD Progressive disease, OS Overall survival.
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widely employed for this purpose, has achieved con-
flicting results. Although a recent work reported in-
creased clinical efficacy of DC vaccination when used in
combination with this alkylating agent, the number of
Foxp3+Tregs remained virtually unchanged [27]. Low-
dose IL-2, widely used as an adjuvant after vaccination,
has been shown to cause a peak in Foxp3+Tregs after
administration which counterbalances the reduction
obtained with cyclophosphamide or daclizumab [28,29].
Taking into consideration these data and our own ex-
perience, we designed a study in which TMZ was added
before vaccination with the aim of reducing the number
of circulating Foxp3+Treg cells. The previous schedule
comprising adjuvant IL-2 for five days after each dose of
vaccine was maintained. Results were not completelyA B
D E
Figure 2 Flow cytometry detection of CD4+CD25++. (A) A dot plot of
lymphocyte population (P1). (B-C) The expression of CD4 and CD25 total ly
control and different gates were drawn to define CD4+CD25_ cells (P2), CD
percentage of CD4+CD25++FoxP3+ cells in total lymhocytes was determin
compared with the negative control.satisfactory. Median overall survival was 10 months,
somewhat lower than the 16 months reported by our
group in a recent update of a previous study [22]. Im-
munological response, evaluated by the DTH skin test,
was also lower. However, in our experience, TMZ
reduced circulating Foxp3+Treg cells in all patients, in-
cluding those who were only treated with the alkylating
agent for 7 days. In fact, we observed a statistically sig-
nificant reduction in Foxp3+Tregs (60%) after the first
cycle, whereas the absolute lymphocyte count only
decreased by 14%, suggesting that the effect of TMZ is
fairly specific for this subpopulation of lymphocytes.
Conversely, IL-2 increased the Foxp3+Treg cell count by
75.4% which, albeit not statistically significant, is consist-
ent with published data. Of note, administration of the
cytokine in the DCR subgroup led to a further decrease
in Foxp3+Treg cells (33.8%), which again was not statis-
tically significant, probably because of the small number
of patients involved. This would seem to indicate that
combined immunological therapy, i.e. TMZ plus den-
dritic cell vaccination plus IL-2, at least for responding
patients, effectively reduced the number of Foxp3+Treg
cells, which showed a poor or null response to the
growth-stimulating effect of IL-2. Of note, PD patients





forward scatter (FSC) and side scatter (SSC) was used to define the
mphocytes (P1) was detected and compared with that of the negative
4+CD25+low-medium cells (P3) and CD4+CD25++ cells (P4). The
ated. (D-E) The histograms show the percentage of FoxP3+Treg cells


























1st cycle 1st cycle 1st cycle 1st cycle 4th cycle 4th cycle 4th cycle 4th cycle
All
patients
−60.5 p = 0.017 −14.2 p = 0.020 +75.4 +15 −5.5 +38.6 −20.3 −4.0
DCR −30.2 −11.9 −33.8 −22.2 −5.3 +53.2 −37.4 −16.4
PD −76.4 p= 0.032 −17.1 +388.9 +32.9 −22 +38.6 −20.3 +7.8
TMZ Temozolomide, IL-2, Interleukin-2, DCR Disease control patients, PD Progressive disease patients.
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versus −30.2%, respectively). Furthermore, a +400%
increase in Foxp3+Tregs was seen in the PD group after
IL-2 administration, whereas values of these lympho-
cytes continued to diminish (−33.8%) in the DCR group.
It can thus be hypothesized that, although PD patients had
a higher quota of proliferating lymphocytes that were sub-
stantially depleted by chemotherapy, the residual cell quota
was still capable of expanding significantly under IL-2
stimulation. Overall, the median Foxp3+Treg cell number
dropped by only −20.3% (range −84.0% – +569.7%) be-
tween baseline values and the end of IL-2 treatment
but was more pronounced in the DCR group (−37.4%;
range −56.8% – +13.2%). Responders once again showed a
greater reduction, albeit not statistically significant, in
Foxp3+Treg cells, without the typical rebound after IL-2.
Noteworthy, Foxp3+Treg cell count showed a continu-
ously decreasing trend in this subgroup, and seven days of
TMZ seem to have been as effective as 14 days, although
this assumption is based on data from only a few patients.































Figure 3 Foxp3+Treg trend in one patient during the first cycle of tem(4 before and 3 after vaccination), and it cannot be ruled
out that this did not influence OS, especially if we take into
account the possible impact of the drug on Foxp3+Tregs.
Conclusions
TMZ reduced the number of circulating Foxp3+Treg cells
in all patients, including those who were treated for 7 days
only. Of note, administration of the cytokine in the DCR
subgroups led to a further decrease in Foxp3+Treg cells
(33.8%), which was not, however, statistically significant,
probably because of the small number of patients in-
volved. This would seem to indicate that combined
immunological therapy, i.e. TMZ plus dendritic cell vac-
cination plus IL-2, at least for responding patients, effect-
ively diminshed the number of Foxp3+Treg cells. The
effect of treatment on Foxp3+Treg cell levels did not lead
to a better clinical outcome, as can be seen from a com-
parison with historical data. Moreover, 7 patients also
received treatment with an anti-CTLA4 antibody, which
may have influenced OS and interfered with the clinical















ozolomide: basal (1), after temozolomide (2) and after IL-2 (3).
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http://www.translational-medicine.com/content/11/1/135interpreted with caution. Further studies are needed to
evaluate the clinical impact of Foxp3+Treg depletion
strategies before vaccine or immunotherapy.
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